The reiteration of a 'Market Outperform' rating and the maintenance of a high price target by a reputable analyst like Jonathan Wolleben can significantly boost investor confidence in Madrigal Pharmaceuticals. This positive outlook is likely to have a favorable impact on the stock price in the short term, as it reaffirms the company's strong potential and growth prospects in the eyes of investors.